Page 1 de 1094 résultats
Nausea and emesis are often observed as side effects with many medicines and may lead to poor treatment compliance. In the present study, we aimed to establish simple methods for predicting nausea and/or emesis in mice, which do not vomit, using drugs and chemicals known to evoke nausea and/or
BACKGROUND
The efficacy of 5-HT(3)-receptor antagonists suggests a role of serotonin in the pathogenesis of postoperative nausea and vomiting (PONV). However, studies investigating the relationship between the turnover of serotonin and PONV were contradictory. Therefore we carried out a pilot study
The experiments on dogs exposed to 137Cs gamma quanta at doses of 8 and 20 Gy showed that Latranum, a selective blocker of serotonin 5-HT3-receptors, is a more efficient antiemetic than Dimetpramidum, a D2-dophamin lytic. This is suggested by fewer animals with emetic reaction or by less severe
The experiments with M. fasciculata monkeys exposed to 137Cs gamma-radiation with a dose of 6.9 Gy showed that Latranum, a blocker of serotonin 5-HT3 receptors, is a more efficient antiemetic than Dimetphramidum, a D2 dophamin lytic. This is suggested by fewer animals with emetic reaction of by less
GR38032F is a specific 5-HT3 (serotonin) receptor antagonist with antiemetic activity in animal and early human studies. We performed a dose-ranging phase I study of GR38032F in 43 evaluable patients receiving cisplatin 60 120 mg/m2 for the first time (38 of these patients were chemotherapy-naive).
Although selective serotonin reuptake inhibitors (SSRIs) are widely used to treat depression, they frequently cause gastrointestinal adverse effects, such as nausea and emesis. In the present study, we investigated the anti-emetic effect of mosapride, a 5-HT(4) receptor agonist, on SSRIs-induced
In order to ensure the continuity of chemotherapy, it is crucial to provide appropriate supportive care to prevent chemotherapy-induced nausea and vomiting (CINV). The frequency of CINV is greatly affected by the type and combination of chemotherapy employed, which requires further investigation.
BACKGROUND
The serotonin type 3 receptor antagonists (5-HT(3) antagonists) ondansetron, granisetron, tropisetron, and dolasetron are potential prophylactic agents for patients with mild to moderate risk of postoperative nausea and vomiting (PONV). A few trials have been conducted to compare the
Chromogranin A (CgA) is present in high concentrations in enterochromaffin cells, where it is co-localised with serotonin in the storage granules. Plasma CgA has been reported to mark emesis and serotonin release associated with cisplatin treatment. However, it is not known whether plasma CgA could
The role of serotonin as the possible trigger mechanism of vomiting associated with chemotherapeutic drugs was further investigated in cancer patients (n = 86). Increases in 5-hydroxyindoleacetic acid (5-HIAA) excretion rates (2.5-2.9 times baseline values) were observed 4 to 8 hours after high-dose
OBJECTIVE
The aim of this study was to determine the mechanism of action of radiation-induced emesis by determining the incidence of radiation-induced emesis following hemibody irradiation; the effects of specific antiemetics especially ondansetron, a 5-hydroxytryptamine receptor antagonist, and to
OBJECTIVE
To examine the association of the serotonin transport gene and postdischarge nausea and vomiting (PDNV) in women following breast cancer surgery.
METHODS
A cross-sectional study.
METHODS
A comprehensive cancer center in Pittsburgh, PA.
METHODS
80 post-menopausal women treated surgically
Postoperative nausea and vomiting (PONV) are common side effects after surgery and have numerous patient factors and etiologies. Although self-limiting, PONV is not without risks and complications. In the past numerous antiemetics have been used successfully in the management of PONV; however, these
Serotonin (5-HT)(3) receptor antagonists are very effective in the control of cisplatin induced emesis. Nevertheless, a significant proportion of patients still experience emesis despite the use of these antiemetics. The aim of this study was to evaluate if cisplatin treated patients who vomit
Patients receiving chemotherapy continue to experience nausea and vomiting despite recent strides to understand the physiology of these symptoms and despite current antiemetic therapies. Ondansetron, a serotonin antagonist, has shown to be a safe and effective drug in alleviating nausea and